Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL11792060 | 0.95 | CA5A (0.46) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| SCHEMBL31339221 | 0.78 | — | — | |
| SCHEMBL10906198 | 0.78 | — | — | |
| SCHEMBL719016 | 0.76 | CA5A (0.38) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| SCHEMBL6552272 | 0.76 | CA5A (0.38) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| SCHEMBL3138751 | 0.70 | CA5A (0.50) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL10981408 | 0.67 | — | — | |
| Nitric Acid SCHEMBL37356 | 0.67 | — | — | |
| Nitric Acid SCHEMBL234 | 0.67 | — | — | |
| Nitric Acid SCHEMBL3762342 | 0.67 | CA5A (1.00) | CA5ACA5BMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835842-B2 | Microbiocides; bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 2004-12-28 | — | — | US | claimed |
| US-20030207929-A1 | 3-nitroisoxazoles and their use in the protection of materials | LANXESS DEUTSCHLAND GMBH (DE) | 2003-11-06 | — | — | US | claimed |
| US-20030166698-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | LANXESS DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | US | claimed |
| EP-1335909-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | Bayer Aktiengesellschaft (DE) | 2003-08-20 | — | — | EP | claimed |
| WO-2002034731-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-02 | — | — | WO | claimed |
| US-7641748-B2 | Highly energy-producing compound | DIEHL BGT DEFENCE GMBH & CO., KG (DE) | 2010-01-05 | — | — | US | disclosed |
| US-20090299106-A1 | HIGHLY ENERGY-PRODUCING COMPOUND | DIEHL BGT DEFENCE GMBH & CO., KG (DE) | 2009-12-03 | — | — | US | disclosed |
| EP-1767519-A1 | Highly energised compounds | Diehl BGT Defence GmbH & Co.KG (DE) | 2007-03-28 | — | — | EP | disclosed |
| US-6835842-B2 | Microbiocides; bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 2004-12-28 | — | — | US | disclosed |
| US-20030207929-A1 | 3-nitroisoxazoles and their use in the protection of materials | LANXESS DEUTSCHLAND GMBH (DE) | 2003-11-06 | — | — | US | disclosed |
| US-6638958-B2 | 3-nitroisoxazoles and their use in the protection of materials | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-28 | — | — | US | disclosed |
| US-20030166698-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | LANXESS DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1335909-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | Bayer Aktiengesellschaft (DE) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002042282-A1 | METHOD FOR PRODUCING NITRO-DIHYDROISOXAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002034731-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-02 | — | — | WO | disclosed |
| WO-2001046163-A2 | 3-NITRO-DIHYDRO-ISOXAZOLES AND OXAZINES AND THEIR USE AS MICROBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-28 | — | — | WO | disclosed |
| US-5332820-A | Diuretic, hypotensive agent, treating congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166698-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | GPX1, NOX1, XDH | CA5A 632/4885CA5B 977/4885MEN1 1505/4885 |
| US-20030207929-A1 | 3-nitroisoxazoles and their use in the protection of materials | GPX1, NOX1, XDH | CA5A 632/4885CA5B 977/4885MEN1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.